Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox W, Grimm S, Howick J, Armstrong N, Ahmadu C, McDermott K, Otten T, Noake C, Wolff R, Joore M. Witlox W, et al. Among authors: ahmadu c. Pharmacoeconomics. 2023 Aug;41(8):857-867. doi: 10.1007/s40273-023-01272-9. Epub 2023 May 2. Pharmacoeconomics. 2023. PMID: 37129774 Free PMC article. Review.
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Orozco Leal G, Armstrong N, Kernohan A, Ahmadu C, Coughlan D, McDermott K, Duffy S, O'Meara S, Robinson T, Vale L, Kleijnen J. Orozco Leal G, et al. Among authors: ahmadu c. Pharmacoeconomics. 2023 Jul;41(7):741-750. doi: 10.1007/s40273-023-01259-6. Epub 2023 Mar 23. Pharmacoeconomics. 2023. PMID: 36952138 Free PMC article. Review.
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Al Khayat MNMT, Armstrong N, Howick J, O'Meara S, Posadzki P, Ryder S, Ahmadu C, Konings SRA, Postma MJ, Duffy S, Wolff RF, van Asselt ADI. Al Khayat MNMT, et al. Among authors: ahmadu c. Pharmacoeconomics. 2023 Apr;41(4):353-361. doi: 10.1007/s40273-023-01247-w. Epub 2023 Feb 9. Pharmacoeconomics. 2023. PMID: 36757608 Free PMC article. Review.
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
van Asselt ADI, Armstrong N, Kimman M, Peeters A, McDermott K, Stirk L, Ahmadu C, Govers TM, Hoentjen F, Joore MA, Grimm SE. van Asselt ADI, et al. Among authors: ahmadu c. Pharmacoeconomics. 2023 Mar;41(3):239-251. doi: 10.1007/s40273-023-01244-z. Epub 2023 Feb 1. Pharmacoeconomics. 2023. PMID: 36725788 Free PMC article. Review.
Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE, Witlox W, Wolff R, Chalker A, Hiligsmann M, Wijnen B, Ahmadu C, Ryder S, Armstrong N, Duffy S, Syndikus I, Kleijnen J, Joore MA. Grimm SE, et al. Among authors: ahmadu c. Pharmacoeconomics. 2022 May;40(5):575. doi: 10.1007/s40273-022-01144-8. Pharmacoeconomics. 2022. PMID: 35364758 Free PMC article. No abstract available.
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE, Witlox W, Wolff R, Chalker A, Hiligsmann M, Wijnen B, Ahmadu C, Ryder S, Armstrong N, Duffy S, Syndikus I, Kleijnen J, Joore MA. Grimm SE, et al. Among authors: ahmadu c. Pharmacoeconomics. 2022 May;40(5):509-518. doi: 10.1007/s40273-021-01098-3. Epub 2021 Oct 19. Pharmacoeconomics. 2022. PMID: 34664200 Free PMC article. Review.